Previous 10 | Next 10 |
CHARLOTTESVILLE, Va. , July 9, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for g...
I first wrote about Horizon Therapeutics ( HZNP ) back in April and had initiated a full position in the company around the time of publication. Since then, Horizon reported its first-quarter results, and its stock has seen a substantial move. This article provides an update on what has change...
Reacting to fiscal Q4 earnings - and some key competitor updates - Nomura Instinet is sticking with a recently initiated Buy rating on "catalyst-rich" Immunovant (NASDAQ: IMVT ) and now sees the company with a long cash runway. More news on: Immunovant, Inc., Horizon Therapeutics Public ...
-- Each share of the FOCUS graphic on social media will generate a donation from Horizon to the patient advocacy organization, Prevent Blindness -- Today, in support of Graves’ Disease Awareness Month, Horizon Therapeutics plc (Nasdaq: HZNP) and Prevent Blindness , the nation...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
This past Friday, Selecta Biosciences ( SELB ) announced a large deal with Swedish Orphan Biovitrum AB [Sobi] ( OTCPK:BIOVF ) worth a possible $730M plus double-digit royalties, with $100M of that upfront. That's quite a large sum for a company that has a current market cap of $234M. Let's l...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Horizon Therapeutics ( HZNP -1.6% ) to redeem all $400M of its 2.50% exchangeable senior notes due 2022 on August 3, 2020. More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Stocks on the move, , Read more ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it issued a notice of redemption for all $400 million of its 2.50% exchangeable senior notes due 2022. The redemption date is August 3, 2020. The exchangeable senior notes may be exchanged by holders at any time before 5 p.m. (Easte...
-- MIRROR open-label trial demonstrates 79 percent of patients achieved a complete response using KRYSTEXXA with methotrexate -- -- Additional data presentations highlight the effect of co-therapy for KRYSTEXXA with two other commonly used immunomodulators, supporting flexible options ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...